467776310	467776310	CD	B-NP	O
|	|	NN	I-NP	O
DCH	DCH	NN	I-NP	O
|	|	NN	I-NP	O
75431077	75431077	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
2686830	2686830	CD	B-NP	O
|	|	CC	I-NP	O
10/23/2006	10/23/2006	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	O
epistaxis	epistaxis	NN	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
9/3/2006	9/3/2006	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Discharge	Discharge	NNP	B-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
5/6/2006	5/6/2006	CD	B-NP	O
******	******	SYM	I-NP	O
FINAL	FINAL	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	O	O
REISINGER	REISINGER	NNP	B-NP	O
,	,	,	O	O
JIMMIE	JIMMIE	NNP	B-NP	O
939-57-15-6	939-57-15-6	CD	I-NP	O
Cra	Cra	NNP	I-NP	O
S	S	NNP	I-NP	O
Son	Son	NNP	I-NP	O
,	,	,	O	O
Hawaii	Hawaii	NNP	B-NP	O
18700	18700	CD	I-NP	O
Service	Service	NNP	I-NP	O
:	:	:	O	O
MED	MED	NNP	B-NP	O
DISCHARGE	DISCHARGE	NNP	I-NP	O
PATIENT	PATIENT	NNP	I-NP	O
ON	ON	NNP	I-NP	O
:	:	:	O	O
6/16/06	6/16/06	CD	B-NP	O
AT	AT	NN	I-NP	O
05	05	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
PM	PM	NN	I-NP	O
CONTINGENT	CONTINGENT	NN	I-NP	O
UPON	UPON	NN	I-NP	O
Attending	Attend	VBG	B-VP	O
evaluation	evaluation	NN	B-NP	O
WILL	WILL	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
ORDER	ORDER	NNP	I-NP	O
BE	BE	NNP	I-NP	O
USED	USED	NNP	I-NP	O
AS	AS	NNP	I-NP	O
THE	THE	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
SUMMARY	SUMMARY	NNP	I-NP	O
:	:	:	O	O
YES	YES	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
MCKESSON	MCKESSON	NNP	B-NP	O
,	,	,	O	O
CHET	CHET	NNP	B-NP	O
RANDOLPH	RANDOLPH	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
M.P.H.	M.P.H.	NNP	B-NP	O
CODE	CODE	NNP	I-NP	O
STATUS	STATUS	NNP	I-NP	O
:	:	:	O	O
Full	Full	JJ	B-NP	O
code	code	NN	I-NP	O
DISPOSITION	DISPOSITION	NN	I-NP	O
:	:	:	O	O
Rehabilitation	Rehabilitation	NN	B-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
LASIX	LASIX	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
FUROSEMIDE	FUROSEMIDE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
40	40	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
ACEBUTOLOL	ACEBUTOLOL	NN	I-NP	O
HCL	HCL	NN	I-NP	O
400	400	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
BID	BID	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Take	Take	NNP	I-NP	O
consistently	consistently	RB	B-ADVP	O
with	with	IN	B-PP	O
meals	meal	NNS	B-NP	O
or	or	CC	B-PP	O
on	on	IN	B-PP	O
empty	empty	JJ	B-NP	O
stomach	stomach	NN	I-NP	O
.	.	.	O	O

FERROUS	FERROUS	NNP	B-NP	O
SULFATE	SULFATE	NNP	I-NP	O
325	325	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
TID	TID	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Avoid	Avoid	NNP	I-NP	O
milk	milk	NN	I-NP	O
and	and	CC	I-NP	O
antacid	antacid	NN	I-NP	O
FOLATE	FOLATE	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
FOLIC	FOLIC	NN	I-NP	O
ACID	ACID	NN	I-NP	O
-RRB-	-RRB-	HYPH	B-NP	O
1	1	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
DAILY	DAILY	NN	I-NP	O
FONDAPARINUX	FONDAPARINUX	NN	I-NP	O
2.5	2.5	CD	I-NP	O
MG	MG	NNP	I-NP	O
SC	SC	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
LISINOPRIL	LISINOPRIL	NNP	I-NP	O
20	20	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
7/30/06	7/30/06	CD	B-NP	O
by	by	IN	B-PP	O
KUMAR	KUMAR	NNP	B-NP	B-protein
,	,	,	O	O
LYMAN	LYMAN	NNP	B-NP	O
A.	A.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
POTASSIUM	POTASSIUM	NNP	B-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
&	&	CC	I-NP	O
LISINOPRIL	LISINOPRIL	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
POTASSIUM	POTASSIUM	NNP	B-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
&	&	CC	I-NP	O
LISINOPRIL	LISINOPRIL	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
MDA	MDA	NN	B-NP	B-DNA
PRAVACHOL	PRAVACHOL	NN	I-NP	I-DNA
-LRB-	-LRB-	NN	I-NP	I-DNA
PRAVASTATIN	PRAVASTATIN	NN	I-NP	I-DNA
-RRB-	-RRB-	NN	I-NP	I-DNA
20	20	CD	I-NP	I-DNA
MG	MG	NNP	I-NP	I-DNA
PO	PO	NNP	I-NP	I-DNA
BEDTIME	BEDTIME	NNP	I-NP	I-DNA
Food/Drug	Food/Drug	NNP	I-NP	I-DNA
Interaction	Interaction	NNP	I-NP	I-DNA
Instruction	Instruction	NNP	I-NP	I-DNA
Avoid	Avoid	NNP	I-NP	I-DNA
grapefruit	grapefruit	NN	I-NP	I-DNA
unless	unless	IN	B-SBAR	I-DNA
MD	MD	NN	B-NP	I-DNA
instructs	instruct	NNS	I-NP	I-DNA
otherwise	otherwise	RB	B-ADVP	O
.	.	.	O	O

DIET	DIET	NN	B-NP	O
:	:	:	O	O
House	House	NNP	B-NP	O
/	/	SYM	B-NP	O
Low	Low	JJ	I-NP	O
chol/low	chol/low	NN	I-NP	O
sat	sat	NN	I-NP	O
.	.	.	O	O

fat	fat	JJ	B-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
2	2	CD	B-NP	O
gram	gram	NN	I-NP	O
Sodium	Sodium	NN	I-NP	O
RETURN	RETURN	NN	I-NP	O
TO	TO	NN	I-NP	O
WORK	WORK	NN	I-NP	O
:	:	:	O	O
Not	Not	NNP	B-NP	O
Applicable	Applicable	NNP	I-NP	O
FOLLOW	FOLLOW	NNP	I-NP	O
UP	UP	NNP	I-NP	O
APPOINTMENT	APPOINTMENT	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
S	S	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
:	:	:	O	O
Winford	Winford	NNP	B-NP	O
Thoele	Thoele	NNP	I-NP	O
,	,	,	O	O
MD	MD	NNP	B-NP	O
scheduled	schedule	VBD	B-VP	O
,	,	,	O	O
Dr	Dr	NNP	B-NP	O
Fraleigh	Fraleigh	NNP	I-NP	O
,	,	,	O	O
Carlos	Carlos	NNP	B-NP	O
5/10	5/10	CD	I-NP	O
1pm	1pm	NN	I-NP	O
scheduled	schedule	VBN	B-VP	O
,	,	,	O	O
ENT	ENT	NN	B-NP	O
clinic	clinic	NN	I-NP	O
scheduled	schedule	VBN	B-VP	O
,	,	,	O	O
ALLERGY	ALLERGY	NN	B-NP	O
:	:	:	O	O
PERCOCET	PERCOCET	NN	B-NP	O
,	,	,	O	O
DICLOXACILLIN	DICLOXACILLIN	NN	B-NP	O
ADMIT	ADMIT	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
:	:	:	O	O
epistaxis	epistaxis	NN	B-NP	O
PRINCIPAL	PRINCIPAL	JJ	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
;	;	:	O	O
Responsible	Responsible	JJ	B-ADJP	O
After	After	IN	B-PP	O
Study	Study	NN	B-NP	O
for	for	IN	B-PP	O
Causing	Cause	VBG	B-VP	O
Admission	Admission	NN	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
epistaxis	epistaxis	NN	I-NP	O
OTHER	OTHER	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
;	;	:	O	O
Conditions	Condition	NNS	B-NP	O
,	,	,	O	O
Infections	Infection	NNS	B-NP	O
,	,	,	O	O
Complications	Complication	NNS	B-NP	O
,	,	,	O	O
affecting	affect	VBG	B-VP	O
Treatment/Stay	Treatment/Stay	NNP	B-NP	O
s/p	s/p	NN	I-NP	O
MVA	MVA	NNP	B-NP	O
8/6	8/6	CD	I-NP	O
s/p	s/p	NN	I-NP	O
B	B	NN	I-NP	O
TKA	TKA	NN	I-NP	O
htn	htn	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
hypertension	hypertension	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
svt	svt	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
supraventricular	supraventricular	JJ	I-NP	O
tachycardia	tachycardia	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
thrombophlebitis	thrombophlebitis	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
superficial	superficial	JJ	I-NP	O
thrombophlebitis	thrombophlebitis	NN	I-NP	O
-RRB-	-RRB-	HYPH	B-NP	O
recurrent	recurrent	JJ	I-NP	O
bilat	bilat	NN	I-NP	O
LE	LE	NN	I-NP	O
cellulitis	cellulitis	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
cellulitis	cellulitis	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
pernicious	pernicious	JJ	I-NP	O
anemia	anemia	NN	I-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
pernicious	pernicious	JJ	I-NP	O
anemia	anemia	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
afib	afib	JJ	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
atrial	atrial	JJ	I-NP	O
fibrillation	fibrillation	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
dvt	dvt	NN	I-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
deep	deep	JJ	I-NP	O
venous	venous	JJ	I-NP	O
thrombosis	thrombosis	NN	I-NP	O
-RRB-	-RRB-	HYPH	B-NP	O
multiple	multiple	JJ	I-NP	O
episodes	episode	NNS	I-NP	O
of	of	IN	B-PP	O
cellulitis	cellulitis	NN	B-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
cellulitis	cellulitis	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
OPERATIONS	OPERATIONS	NNS	I-NP	O
AND	AND	CC	I-NP	O
PROCEDURES	PROCEDURES	NNS	I-NP	O
:	:	:	O	O
none	none	NN	B-NP	O
OTHER	OTHER	NN	I-NP	O
TREATMENTS/PROCEDURES	TREATMENTS/PROCEDURES	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
NOT	NOT	NNP	I-NP	O
IN	IN	NNP	I-NP	O
O.R.	O.R.	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
anterior	anterior	JJ	I-NP	O
nare	nare	NN	I-NP	O
cauterization	cauterization	NN	I-NP	O
for	for	IN	B-PP	O
nosebleed	nosebleed	NN	B-NP	O
BRIEF	BRIEF	NN	I-NP	O
RESUME	RESUME	NN	I-NP	O
OF	OF	IN	B-PP	O
HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
PCP	PCP	NN	B-NP	O
:	:	:	O	O
Wendell	Wendell	NNP	B-NP	O
Henfling	Henfling	NNP	I-NP	O
,	,	,	O	O
Oncologist	Oncologist	NNP	B-NP	O
:	:	:	O	O
Gene	Gene	NNP	B-NP	O
Fretwell	Fretwell	NNP	I-NP	O
CC	CC	NNP	I-NP	O
:	:	:	O	O
epistaxis	epistaxis	NN	B-NP	O
HPI	HPI	NN	I-NP	O
:	:	:	O	O
80	80	CD	B-NP	O
y/o	y/o	NN	I-NP	O
F	F	NN	I-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
PMH	PMH	NN	I-NP	O
of	of	IN	B-PP	O
DVT	DVT	NN	B-NP	O
on	on	IN	B-PP	O
coumadin	coumadin	NN	B-NP	O
,	,	,	O	O
Afib	Afib	NN	B-NP	O
,	,	,	O	O
non-small	non-small	JJ	B-NP	O
cell	cell	NN	I-NP	O
ca	ca	NN	I-NP	O
s/p	s/p	NN	I-NP	O
resection	resection	NN	I-NP	O
on	on	IN	B-PP	O
tarceva	tarceva	NN	B-NP	O
,	,	,	O	O
morbid	morbid	NN	B-NP	O
obesity	obesity	NN	I-NP	O
that	that	WDT	B-NP	O
presents	present	VBZ	B-VP	O
w	w	NN	B-NP	O
/	/	SYM	B-NP	O
persistent	persistent	JJ	I-NP	O
epistaxis	epistaxis	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
actually	actually	RB	I-VP	O
seen	see	VBN	I-VP	O
by	by	IN	B-PP	O
ENT	ENT	NN	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
ED	ED	NN	I-NP	O
on	on	IN	B-PP	O
5/13	5/13	CD	B-NP	O
,	,	,	O	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
an	an	DT	B-NP	O
anterior	anterior	JJ	I-NP	O
R	R	NN	I-NP	O
nare	nare	NN	I-NP	O
bleed	bleed	NN	I-NP	O
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
cauterized	cauterize	VBN	I-VP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
sent	send	VBN	I-VP	O
home	home	NN	B-ADVP	O
.	.	.	O	O

Later	Later	RB	B-ADVP	O
that	that	DT	B-NP	O
night	night	NN	I-NP	O
she	she	PRP	B-NP	O
woke	wake	VBD	B-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
nosebleed	nosebleed	NN	I-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
came	come	VBD	B-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
ED	ED	NN	I-NP	O
when	when	WRB	B-ADVP	O
the	the	DT	B-NP	O
bleeding	bleeding	NN	I-NP	O
persisted	persist	VBD	B-VP	O
.	.	.	O	O

VS	VS	NN	B-NP	B-protein
60	60	CD	I-NP	I-protein
92/52	92/52	CD	I-NP	I-protein
96	96	CD	I-NP	I-protein
%	%	NN	I-NP	I-protein
RA	RA	NN	I-NP	I-protein
with	with	IN	B-PP	O
some	some	DT	B-NP	O
lightheadedness	lightheadedness	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
bleed	bleed	VB	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
ED	ED	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
hct	hct	NN	I-NP	O
was	be	VBD	B-VP	O
24	24	CD	B-NP	O
down	down	IN	B-ADVP	O
from	from	IN	B-PP	O
27	27	CD	B-NP	O
on	on	IN	B-PP	O
5/13	5/13	CD	B-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
3	3	CD	I-NP	I-protein
-LRB-	-LRB-	HYPH	B-NP	O
2.7	2.7	CD	I-NP	O
on	on	IN	B-PP	O
5/13	5/13	CD	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
transfused	transfuse	VBN	I-VP	O
2U	2U	NN	B-NP	O
PRBCs	PRBC	NNS	I-NP	O
and	and	CC	O	O
3U	3U	NN	B-NP	O
FFP	FFP	NN	I-NP	O
.	.	.	O	O

ENT	ENT	NN	B-NP	O
was	be	VBD	B-VP	O
consulted	consult	VBN	I-VP	O
and	and	CC	O	O
the	the	DT	B-NP	O
anterior	anterior	JJ	I-NP	O
R	R	NN	I-NP	O
nare	nare	NN	I-NP	O
was	be	VBD	B-VP	O
cauterized	cauterize	VBN	I-VP	O
successfully	successfully	RB	B-ADVP	O
.	.	.	O	O

***	***	SYM	B-NP	O
PMH	PMH	NN	I-NP	O
:	:	:	O	O
DVT	DVT	NN	B-NP	O
on	on	IN	B-PP	O
coumadin	coumadin	NN	B-NP	O
,	,	,	O	O
Afib	Afib	NN	B-NP	O
,	,	,	O	O
non-small	non-small	JJ	B-NP	O
cell	cell	NN	I-NP	O
ca	ca	NN	I-NP	O
s/p	s/p	NN	I-NP	O
resection	resection	NN	I-NP	O
on	on	IN	B-PP	O
tarceva	tarceva	NN	B-NP	O
,	,	,	O	O
morbid	morbid	NN	B-NP	O
obesity	obesity	NN	I-NP	O
***	***	SYM	B-VP	O
Meds	Med	NNS	B-NP	O
on	on	IN	B-PP	O
admit	admit	NN	B-NP	O
:	:	:	O	O
coumadin	coumadin	NN	B-NP	O
,	,	,	O	O
asa	asa	NN	B-NP	O
,	,	,	O	O
lisinopril	lisinopril	NN	B-NP	O
,	,	,	O	O
tarceva	tarceva	NN	B-NP	O
,	,	,	O	O
b12	b12	NN	B-NP	B-protein
,	,	,	O	O
folate	folate	NN	B-NP	O
,	,	,	O	O
lasix	lasix	NN	B-NP	O
,	,	,	O	O
pravachol	pravachol	NN	B-NP	O
,	,	,	O	O
allopurinol	allopurinol	NN	B-NP	O
Allergies	Allergy	NNS	I-NP	O
:	:	:	O	O
percocet	percocet	NN	B-NP	O
,	,	,	O	O
dicloxacillin	dicloxacillin	NN	B-NP	O
***	***	SYM	B-NP	O
Exam	Exam	NN	I-NP	O
on	on	IN	B-PP	O
admition	admition	NN	B-NP	O
:	:	:	O	O
AF	AF	NN	B-NP	O
66122/64	66122/64	CD	I-NP	O
20	20	CD	I-NP	O
99	99	CD	I-NP	O
%	%	NN	I-NP	O
RA	RA	NN	I-NP	O
obese	obese	NN	I-NP	O
,	,	,	O	O
NAD	NAD	NN	B-NP	O
not	not	RB	B-VP	O
bleeding	bleed	VBG	I-VP	O
,	,	,	O	O
RRR	RRR	NN	B-NP	B-protein
,	,	,	O	O
2/6	2/6	CD	B-NP	O
SEM	SEM	NNP	I-NP	O
LUSB	LUSB	NNP	I-NP	O
,	,	,	O	O
crackles	crackle	NNS	B-NP	O
at	at	IN	B-PP	O
bases	base	NNS	B-NP	O
,	,	,	O	O
abd	abd	NN	B-NP	O
benign	benign	JJ	B-ADJP	O
,	,	,	O	O
trace	trace	NN	B-NP	O
LE	LE	NNP	I-NP	O
edema	edema	NNP	I-NP	O
***	***	NNP	I-NP	O
LABS	LABS	NNP	I-NP	O
:	:	:	O	O
hct	hct	VB	B-VP	O
24.4	24.4	CD	B-NP	O
wbc	wbc	NN	I-NP	O
4.7	4.7	CD	B-NP	O
,	,	,	O	O
plt	plt	NN	B-NP	B-protein
211	211	CD	I-NP	I-protein
,	,	,	O	O
INR	INR	NN	B-NP	B-protein
3	3	CD	I-NP	I-protein
,	,	,	O	O
CR	CR	NN	B-NP	B-protein
1.3	1.3	CD	I-NP	I-protein
***	***	SYM	I-NP	O
ECG	ECG	NN	I-NP	O
:	:	:	O	O
NSR	NSR	NN	B-NP	O
60s	60	NNS	I-NP	O
,	,	,	O	O
1st	1st	JJ	B-NP	O
degree	degree	NN	I-NP	O
AV	AV	NN	I-NP	O
block	block	NN	I-NP	O
,	,	,	O	O
nl	nl	NN	B-NP	O
axis	axis	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
acute	acute	JJ	I-NP	O
ST	ST	NN	I-NP	O
changes	change	NNS	I-NP	O
***	***	SYM	B-NP	O
exam	exam	NN	I-NP	O
on	on	IN	B-PP	O
d/c	d/c	NN	B-NP	O
:	:	:	O	O
unchanged	unchanged	JJ	B-NP	O
labs	lab	NNS	I-NP	O
on	on	IN	B-PP	O
d/c	d/c	NN	B-NP	O
:	:	:	O	O
cr1	cr1	NN	B-NP	O
.2	.2	NN	I-NP	O
,	,	,	O	O
hct	hct	NN	B-NP	B-protein
26.5	26.5	CD	I-NP	I-protein
,	,	,	O	O
INR	INR	NN	B-NP	O
1.2	1.2	CD	I-NP	O
**********	**********	SYM	I-NP	O
Daily	Daily	JJ	I-NP	O
events	event	NNS	I-NP	O
:	:	:	O	O
PCP	PCP	NN	B-NP	O
and	and	CC	I-NP	O
oncologist	oncologist	NN	I-NP	O
to	to	TO	B-VP	O
decide	decide	VB	I-VP	O
appropriate	appropriate	JJ	B-NP	O
anticoagulation	anticoagulation	NN	I-NP	O
regimen	regimen	NN	I-NP	O
for	for	IN	B-PP	O
pt	pt	NN	B-NP	O
.	.	.	O	O

***	***	SYM	B-NP	O
A/P	A/P	NN	I-NP	O
:	:	:	O	O
80	80	CD	B-NP	O
y/o	y/o	NN	I-NP	O
F	F	NN	I-NP	O
h/o	h/o	NN	I-NP	O
DVT	DVT	NN	I-NP	O
on	on	IN	B-PP	O
coumadin	coumadin	NN	B-NP	O
,	,	,	O	O
non-small	non-small	JJ	B-NP	O
cell	cell	NN	I-NP	O
ca	ca	NN	I-NP	O
s/p	s/p	NN	I-NP	O
resection	resection	NN	I-NP	O
on	on	IN	B-PP	O
tarceva	tarceva	NN	B-NP	O
,	,	,	O	O
morbid	morbid	NN	B-NP	O
obesity	obesity	NN	I-NP	O
presents	present	VBZ	B-VP	O
with	with	IN	B-PP	O
persistent	persistent	JJ	B-NP	O
nosebleeds	nosebleed	NNS	I-NP	O
.	.	.	O	O

1	1	LS	B-LST	O
.	.	.	O	O

Epistaxis	Epistaxis	NN	B-NP	O
-	-	HYPH	I-NP	O
s/p	s/p	NN	I-NP	O
cauterization	cauterization	NN	I-NP	O
by	by	IN	B-PP	O
ENT	ENT	NN	B-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
recurrence	recurrence	NN	I-NP	O
.	.	.	O	O

Off	Off	IN	B-PP	O
coumadin	coumadin	NN	B-NP	O
s/p	s/p	NN	I-NP	O
3U	3U	NN	I-NP	O
FFP	FFP	NN	I-NP	O
with	with	IN	B-PP	O
INR	INR	NN	B-NP	B-protein
1.8	1.8	CD	I-NP	I-protein
.	.	.	O	O

Will	Will	MD	B-VP	O
hold	hold	VB	I-VP	O
off	off	RP	B-PRT	O
on	on	IN	B-PP	O
coumadin	coumadin	NN	B-NP	O
for	for	IN	B-PP	O
now	now	RB	B-ADVP	O
and	and	CC	O	O
allow	allow	VB	B-VP	O
for	for	IN	B-PP	O
nose	nose	NN	B-NP	O
bleed	bleed	NN	I-NP	O
to	to	TO	B-PP	O
fully	fully	RB	B-ADJP	O
heal	heal	JJ	I-ADJP	O
.	.	.	O	O

PCP	PCP	NN	B-NP	O
contacted	contact	VBD	B-VP	O
and	and	CC	O	O
after	after	IN	B-PP	O
communication	communication	NN	B-NP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
pt	pt	NN	I-NP	O
's	's	POS	B-NP	O
oncologist	oncologist	NN	I-NP	O
the	the	DT	B-NP	O
plan	plan	NN	I-NP	O
is	be	VBZ	B-VP	O
to	to	TO	B-VP	O
stop	stop	VB	I-VP	O
tarceva	tarceva	NN	B-NP	O
for	for	IN	B-PP	O
now	now	RB	B-NP	O
until	until	IN	B-SBAR	O
she	she	PRP	B-NP	O
sees	see	VBZ	B-VP	O
her	her	PRP$	B-NP	O
oncologist	oncologist	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
will	will	MD	B-VP	O
also	also	RB	I-VP	O
be	be	VB	I-VP	O
off	off	RP	B-PRT	O
coumadin	coumadin	NN	B-NP	O
and	and	CC	O	O
start	start	VB	B-VP	O
on	on	IN	B-PP	O
Arixtra	Arixtra	NNP	B-NP	O
2.5	2.5	CD	I-NP	O
mg	mg	NN	I-NP	O
SC	SC	NNP	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

h/o	h/o	NN	B-NP	O
DVT	DVT	NN	I-NP	O
-	-	HYPH	B-NP	O
appears	appear	VBZ	B-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
been	be	VBN	I-VP	O
on	on	IN	B-PP	O
coumadin	coumadin	NN	B-NP	O
as	as	RB	B-ADVP	O
far	far	RB	I-ADVP	O
back	back	RB	B-ADVP	O
as	as	IN	B-PP	O
1993	1993	CD	B-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
documented	document	VBN	I-NP	O
h/o	h/o	NN	I-NP	O
L	L	NN	I-NP	O
superficial	superficial	JJ	I-NP	O
femoral	femoral	JJ	I-NP	O
vein	vein	NN	I-NP	O
DVT	DVT	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
multiple	multiple	JJ	B-NP	O
risk	risk	NN	I-NP	O
factors	factor	NNS	I-NP	O
for	for	IN	B-PP	O
DVT	DVT	NN	B-NP	O
inclding	inclde	VBG	B-VP	O
morbid	morbid	NN	B-NP	O
obesity	obesity	NN	I-NP	O
,	,	,	O	O
malignancy	malignancy	NN	B-NP	O
and	and	CC	O	O
prior	prior	JJ	B-NP	O
h/o	h/o	NN	I-NP	O
DVT	DVT	NN	I-NP	O
she	she	PRP	B-NP	O
will	will	MD	B-VP	O
require	require	VB	I-VP	O
continuation	continuation	NN	B-NP	O
of	of	IN	B-PP	O
anticoagulation	anticoagulation	NN	B-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
's	's	POS	B-NP	O
oncologist	oncologist	NN	I-NP	O
Dr.	Dr.	NNP	I-NP	O
Reges	Reges	NNP	I-NP	O
aware	aware	JJ	I-NP	O
and	and	CC	O	O
recommends	recommend	VBZ	B-VP	O
stopping	stop	VBG	I-VP	O
coumadin	coumadin	NN	B-NP	O
and	and	CC	O	O
starting	start	VBG	B-NP	O
arixtra	arixtra	NNS	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Heme	Heme	NN	B-NP	B-protein
-	-	HYPH	B-PP	O
transfused	transfuse	VBN	B-NP	O
2U	2U	NN	I-NP	O
PRBCS	PRBCS	NN	I-NP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
and	and	CC	O	O
no	no	DT	B-NP	O
further	further	JJ	I-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
bleeding	bleed	VBG	B-NP	O
.	.	.	O	O

Hct	Hct	NN	B-NP	O
stable	stable	JJ	B-ADJP	O
at	at	IN	B-PP	O
26	26	CD	B-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
transfused	transfuse	VBN	I-VP	O
an	an	DT	B-NP	O
additional	additional	JJ	I-NP	O
1UPRBC	1UPRBC	NN	I-NP	O
before	before	IN	B-PP	O
d/c	d/c	NN	B-NP	O
.	.	.	O	O

FEN	FEN	NN	B-NP	O
-	-	HYPH	I-NP	O
cardiac	cardiac	JJ	I-NP	B-protein
diet	diet	NN	I-NP	I-protein
6	6	CD	I-NP	I-protein
.	.	.	O	O

Full	Full	DT	B-NP	O
code	code	VBP	B-VP	O
ADDITIONAL	ADDITIONAL	JJ	B-NP	O
COMMENTS	COMMENTS	NNS	I-NP	O
:	:	:	O	O
Please	Please	NN	B-NP	B-protein
stop	stop	VB	B-VP	O
taking	take	VBG	I-VP	O
coumadin	coumadin	NN	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
warfarin	warfarin	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
.	.	.	O	O

Also	Also	RB	B-ADVP	O
stop	stop	VB	B-VP	O
taking	take	VBG	I-VP	O
TARCEVA	TARCEVA	NN	B-NP	O
until	until	IN	B-SBAR	O
you	you	PRP	B-NP	O
follow	follow	VBP	B-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
your	your	PRP$	B-NP	O
oncologist	oncologist	NN	I-NP	O
.	.	.	O	O

Please	Please	NNP	B-NP	O
use	use	VBP	B-VP	O
Ocean	Ocean	NNP	B-NP	O
nasal	nasal	JJ	I-NP	O
spray	spray	NN	I-NP	O
starting	start	VBG	B-VP	O
2/8	2/8	CD	B-NP	O
to	to	TO	B-VP	O
keep	keep	VB	I-VP	O
nose	nose	RB	B-ADJP	O
from	from	IN	B-PP	O
getting	get	VBG	B-VP	O
dry	dry	JJ	B-ADJP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
CONDITION	CONDITION	NN	I-NP	O
:	:	:	O	O
Stable	Stable	JJ	B-NP	O
TO	TO	NN	I-NP	O
DO/PLAN	DO/PLAN	NN	I-NP	O
:	:	:	O	O
Stop	Stop	NN	B-NP	O
coumadin	coumadin	NN	I-NP	O
and	and	CC	O	O
tarceva	tarceva	NN	B-NP	O
until	until	IN	B-PP	O
f/u	f/u	NN	B-NP	O
with	with	IN	B-PP	O
oncologist	oncologist	NN	B-NP	O
.	.	.	O	O

Start	Start	NN	B-NP	O
anticoagulation	anticoagulation	NN	I-NP	O
with	with	IN	B-PP	O
Arixtra	Arixtra	NNP	B-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
dictated	dictated	JJ	I-NP	O
summary	summary	NN	I-NP	O
ENTERED	ENTERED	NNP	I-NP	O
BY	BY	NNP	I-NP	O
:	:	:	O	O
TURNBILL	TURNBILL	NNP	B-NP	O
,	,	,	O	O
ASHLEY	ASHLEY	NNP	B-NP	O
I.	I.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
HN46	HN46	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
4/22/06	4/22/06	CD	I-NP	O
@	@	NN	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
06	06	CD	B-NP	O
PM	PM	NN	I-NP	O
******	******	SYM	B-NP	O
END	END	NN	I-NP	O
OF	OF	IN	B-PP	O
DISCHARGE	DISCHARGE	NN	B-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	B-NP	O

